News

GRP named a top economic development organization in the U.S.

RICHMOND, VA – The Greater Richmond Partnership (GRP) was named among the top 20 economic development organizations in the nation according to Site Selection magazine, a national publication targeting site location professionals and corporate executives making relocation decisions.

The 2022 Mac Conway Awards for Excellence in Economic Development, named in honor of Site Selection founding publisher H. McKinley ‘Mac’ Conway, are awarded annually to the top economic development organizations in the country determined by an index of corporate job creation and facility-related capital investment data calculated both cumulatively and per capita. This marks the first time since 2015 the publication has recognized GRP for outstanding work in its field. It was named a top organization four previous years plus two honorable mentions since its inception in 1994.

“In the last two years, we’ve done a lot of work to come out of the pandemic as a stronger and more focused region and organization. This includes benchmarking best of class regions and regional groups,” said Jennifer Wakefield, President and CEO of GRP. “We are thrilled to be recognized among the best economic development organizations in the country yet again. It’s a testament to our strong public-private partnership and the collaboration found throughout the region to bring jobs and investment to Greater Richmond.”

Earlier this year, Site Selection ranked Greater Richmond as the 3rd top metro for economic development projects per capita for 2021.

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business